Metrics to compare | 4591 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4591PeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.6x | −8.6x | −0.3x | |
PEG Ratio | −0.43 | −0.23 | 0.00 | |
Price/Book | 1.5x | 3.1x | 2.6x | |
Price / LTM Sales | 1,376.0x | 20.6x | 3.0x | |
Upside (Analyst Target) | - | 154.1% | 56.7% | |
Fair Value Upside | Unlock | 14.3% | 9.4% | Unlock |
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.